Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28


Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol.

Thomas SK, Cha SC, Smith DL, Kim KH, Parshottam SR, Rao S, Popescu M, Lee VY, Neelapu SS, Kwak LW.

BMC Cancer. 2018 Feb 13;18(1):187. doi: 10.1186/s12885-018-4094-2.


Disease control should be the goal of therapy for WM patients.

Kastritis E, Dimopoulos MA.

Blood Adv. 2017 Nov 28;1(25):2483-2485. doi: 10.1182/bloodadvances.2017005645. eCollection 2017 Nov 28.


Waldenstrom's Macroglobulinemia: A Report of Two Cases, One with Severe Retinopathy and One with Renal Failure.

Kudo N, Usui M, Nakabo Y, Yoshida KI, Miki K, Osafune T, Nishimura K, Imashuku S.

Case Rep Hematol. 2017;2017:3732902. doi: 10.1155/2017/3732902. Epub 2017 Oct 31.


BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.

Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiègue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2016 Jun 7;8(34):57451-57459. doi: 10.18632/oncotarget.9917. eCollection 2017 Aug 22.


Waldenström Macroglobulinemia: Review of Pathogenesis and Management.

Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, Baz RC, Anwer F.

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):252-262. doi: 10.1016/j.clml.2017.02.028. Epub 2017 Mar 7. Review.


New developments in the management of Waldenström macroglobulinemia.

Abeykoon JP, Yanamandra U, Kapoor P.

Cancer Manag Res. 2017 Mar 10;9:73-83. doi: 10.2147/CMAR.S94059. eCollection 2017. Review.


Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB.

JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763. Review.


Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.

Kyle RA, Ansell SM, Kapoor P.

Best Pract Res Clin Haematol. 2016 Jun;29(2):179-186. doi: 10.1016/j.beha.2016.08.014. Epub 2016 Aug 23. Review.


Immunoglobulin M 'Flare' Seen in a Case of Waldenstrom's Macroglobulinemia: Successfully Managed by Therapeutic Plasma Exchange.

Datta SS, Mukherjee S, Talukder B, Bhattacharya P.

Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):148-51. doi: 10.1007/s12288-015-0603-5. Epub 2015 Sep 29.


Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E.

Br J Haematol. 2016 Oct;175(1):77-86. doi: 10.1111/bjh.14196. Epub 2016 Jul 5.


Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.

Kastritis E, Kyrtsonis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, Dimopoulos MA.

Haematologica. 2015 Nov;100(11):e446-9. doi: 10.3324/haematol.2015.124149. Epub 2015 Aug 20. No abstract available.


Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15. Review.


How to manage Waldenstrom's macroglobulinemia.

Buske C, Leblond V.

Leukemia. 2013 Apr;27(4):762-72. doi: 10.1038/leu.2013.36. Epub 2013 Feb 6. Review.


Progression in smoldering Waldenstrom macroglobulinemia: long-term results.

Kyle RA, Benson JT, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Melton LJ 3rd, Rajkumar SV.

Blood. 2012 May 10;119(19):4462-6. doi: 10.1182/blood-2011-10-384768. Epub 2012 Mar 26.


Novel agents in Waldenström macroglobulinemia.

Issa GC, Ghobrial IM, Roccaro AM.

Clin Investig (Lond). 2011;1(6):815-824.


New Therapeutic Approaches for Waldenstrom Macroglobulinemia.

Stedman J, Roccaro A, Leleu X, Ghobrial IM.

Drugs Future. 2010 Jan;35(1):53-58.


Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M.

Blood. 2011 Jul 14;118(2):276-81. doi: 10.1182/blood-2011-02-338558. Epub 2011 May 12.


Robert Arthur Kyle, MD: a conversation with the editor.

Kyle RA, Roberts WC.

Proc (Bayl Univ Med Cent). 2010 Oct;23(4):400-18. No abstract available.


Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA.

Mayo Clin Proc. 2010 Sep;85(9):824-33. doi: 10.4065/mcp.2010.0304. Epub 2010 Aug 11. Review.


Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE.

J Clin Oncol. 2010 Mar 10;28(8):1408-14. doi: 10.1200/JCO.2009.24.0994. Epub 2010 Feb 8.

Supplemental Content

Support Center